세계의 난소암 시장 점유율, 규모, 동향, 산업 분석 리포트 : 유형별, 진단별, 치료법별, 최종사용자별, 지역별, 부문 예측(2022-2030년)

The global ovarian cancer market is expected to reach USD 9.67 billion by 2030, according to a new study by Polaris Market Research. The report "Ovarian Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Epithelial Tumors, Germ Cell Tumors, Stromal Tumors, and Primary Peritoneal Cancer); By Diagnosis; By Therapeutic Treatment; By End-User; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market expansion is anticipated to be fueled by the growing emphasis on early diagnosis and treatment and rising FDA approvals for the treatment. The disease prognosis is still bleak because most patients only receive advanced-stage diagnoses. For instance, in November 2021, an imaging medication called Cytalux (pafolacianine), meant to help surgeons spot ovarian cancer lesions, received approval from the U.S. Food and Drug Administration. The medication makes it easier to find extra ovarian malignant tissue, which is typically challenging during surgery.

Further, in May 2020, the FDA authorized Lynparza in conjunction with bevacizumab as the initial maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or principal peritoneal cancer, according to an alliance from AstraZeneca and Merck. Therefore, there is a critical need for an in-depth study of disease biology to create potent therapeutic choices to overcome resistance and reduce toxicity.

The market is expected to be driven by increased government initiatives, rising R&D activities in cancer research, and the ease of use of new treatments and therapies. For instance, the Ovarian Cancer Research Alliance (OCRA), a non-profit group, focuses on cancer research and development. Top researchers at 79 eminent medical centers have received 349 grants totaling $110 million from OCRA, ensuring that research into ovarian cancer continues to advance the field and prepare the way for a solution. It funds several research initiatives aimed at identifying and treating this condition. Thus, these factors bolster industry growth during the forecast period.

Healthcare is expanding as a result of the rising economy of the nations in both developed and emerging regions. The industry is expected to continue to increase during the forecast period due to factors such as the rising incidence of ovarian cancer and the growing number of elderly women. According to the National Institute of Health, 604 million old women will exist worldwide by 2025.

Ovarian Cancer Market Report Highlights

Targeted therapy is anticipated to grow rapidly over the forecast period because it interfaces with specific proteins in tumorigenesis by focusing on molecular changes which stop the growth of various types of cancers. Also, targeted medicines are becoming more and more popular.

CT Scans segment accounted for a higher revenue share. Due to its capacity to shed light on tumor dissemination, CT scan demand in cancer diagnostics is anticipated to rise.

Asia-Pacific is expected to grow faster over the projected period due to the increasing prevalence of the geriatric population in emerging economies, improved healthcare infrastructure, rising disposable income, and increased consumer awareness regarding health.

The global market is highly competitive owing to the existence of significant players with a global presence, including AstraZeneca Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Corp., Janssen Pharmaceuticals, Inc., Novogen, Inc., Oasmia Pharmaceutical Inc, Pfizer Inc., Roche Ltd., and Tesaro Inc.

Polaris Market Research has segmented the Ovarian Cancer market report based on type, diagnosis, therapeutic treatment, end-user, and region:

Ovarian Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Epithelial Tumors

Germ Cell Tumors

Stromal Tumors

Primary Peritoneal Cancer

Ovarian Cancer, Diagnosis Outlook (Revenue - USD Billion, 2018 - 2030)

Computed Tomography (C.T.) Scans

Ultrasound

Barium Enema X-Ray

Magnetic Resonance Imaging (MRI) Scans

Chest X-Ray

Positron Emission Tomography (PET) Scan

Other Diagnostic Tests

Ovarian Cancer, Therapeutic Treatment Outlook (Revenue - USD Billion, 2018 - 2030)

Chemotherapy

Radiation Therapy

Targeted Therapy

Hormone Therapy

Other Therapeutic Treatments

Surgery

Ovarian Cancer, End-User Outlook (Revenue - USD Billion, 2018 - 2030)

Hospitals

Diagnostic Centers

Drug Stores

Online Pharmacies

Other End Users

Ovarian Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Ovarian Cancer Market Insights

• 4.1. Ovarian Cancer - Industry Snapshot
• 4.2. Ovarian Cancer Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rise in the Elderly women's population
    • 4.2.1.2. Rising healthcare awareness is accelerating the market
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Ignorance of the symptoms of Ovarian Cancer may drag down the market
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Ovarian Cancer Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Ovarian Cancer Market, by Diagnosis

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
• 5.3. Computed Tomography (C.T.) Scans
  • 5.3.1. Global Ovarian Cancer Market, by Computed Tomography (C.T.) Scans, by Region, 2018 - 2030 (USD Billion)
• 5.4. Ultrasound
  • 5.4.1. Global Ovarian Cancer Market, by Ultrasound, by Region, 2018 - 2030 (USD Billion)
• 5.5. Barium Enema X-Ray
  • 5.5.1. Global Ovarian Cancer Market, by Barium Enema X-Ray, by Region, 2018 - 2030 (USD Billion)
• 5.6. Magnetic Resonance Imaging (MRI) Scans
  • 5.6.1. Global Ovarian Cancer Market, by Magnetic Resonance Imaging (MRI) Scans, by Region, 2018 - 2030 (USD Billion)
• 5.7. Chest X-Ray
  • 5.7.1. Global Ovarian Cancer Market, by Chest X-Ray, by Region, 2018 - 2030 (USD Billion)
• 5.8. Positron Emission Tomography (PET) Scan
  • 5.8.1. Global Ovarian Cancer Market, by Positron Emission Tomography (PET) Scan, by Region, 2018 - 2030 (USD Billion)
• 5.9. Other Diagnostic Tests
  • 5.9.1. Global Ovarian Cancer Market, by Other Diagnostic Tests, by Region, 2018 - 2030 (USD Billion)

6. Global Ovarian Cancer Market, by Therapeutic Treatment

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
• 6.3. Chemotherapy
  • 6.3.1. Global Ovarian Cancer Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)
• 6.4. Radiation Therapy
  • 6.4.1. Global Ovarian Cancer Market, by Radiation Therapy, by Region, 2018 - 2030 (USD Billion)
• 6.5. Targeted Therapy
  • 6.5.1. Global Ovarian Cancer Market, by Targeted Therapy, by Region, 2018 - 2030 (USD Billion)
• 6.6. Hormone Therapy
  • 6.6.1. Global Ovarian Cancer Market, by Hormone Therapy, by Region, 2018 - 2030 (USD Billion)
• 6.7. Other Therapeutic Treatments
  • 6.7.1. Global Ovarian Cancer Market, by Other Therapeutic Treatments, by Region, 2018 - 2030 (USD Billion)
• 6.8. Surgery
  • 6.8.1. Global Ovarian Cancer Market, by Surgery, by Region, 2018 - 2030 (USD Billion)

7. Global Ovarian Cancer Market, by Type

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
• 7.3. Epithelial Tumors
  • 7.3.1. Global Ovarian Cancer Market, by Epithelial Tumors, by Region, 2018 - 2030 (USD Billion)
• 7.4. Germ Cell Tumors
  • 7.4.1. Global Ovarian Cancer Market, by Germ Cell Tumors, by Region, 2018 - 2030 (USD Billion)
• 7.5. Stromal Tumors
  • 7.5.1. Global Ovarian Cancer Market, by Stromal Tumors, by Region, 2018 - 2030 (USD Billion)
• 7.6. Primary Peritoneal Cancer
  • 7.6.1. Global Ovarian Cancer Market, by Primary Peritoneal Cancer, by Region, 2018 - 2030 (USD Billion)

8. Global Ovarian Cancer Market, by End-User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Ovarian Cancer Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)
• 8.4. Diagnostic Centers
  • 8.4.1. Global Ovarian Cancer Market, by Diagnostic Centers, by Region, 2018 - 2030 (USD Billion)
• 8.5. Drug Stores
  • 8.5.1. Global Ovarian Cancer Market, by Drug Stores, by Region, 2018 - 2030 (USD Billion)
• 8.6. Online Pharmacies
  • 8.6.1. Global Ovarian Cancer Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
• 8.7. Other End Users
  • 8.7.1. Global Ovarian Cancer Market, by Other End Users, by Region, 2018 - 2030 (USD Billion)

9. Global Ovarian Cancer Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Ovarian Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• 9.3. Ovarian Cancer Market - North America
  • 9.3.1. North America: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 9.3.2. North America: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 9.3.3. North America: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 9.3.4. North America: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.3.5. Ovarian Cancer Market - U.S.
    • 9.3.5.1. U.S.: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.3.5.2. U.S.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.3.5.3. U.S.: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.3.5.4. U.S.: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.3.6. Ovarian Cancer Market - Canada
    • 9.3.6.1. Canada: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.3.6.2. Canada: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.3.6.3. Canada: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.3.6.4. Canada: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
• 9.4. Ovarian Cancer Market - Europe
  • 9.4.1. Europe: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 9.4.2. Europe: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 9.4.3. Europe: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 9.4.4. Europe: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.5. Ovarian Cancer Market - UK
    • 9.4.5.1. UK: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.5.2. UK: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.5.3. UK: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.5.4. UK: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.6. Ovarian Cancer Market - France
    • 9.4.6.1. France: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.6.2. France: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.6.3. France: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.6.4. France: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.7. Ovarian Cancer Market - Germany
    • 9.4.7.1. Germany: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.7.2. Germany: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.7.3. Germany: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.7.4. Germany: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.8. Ovarian Cancer Market - Italy
    • 9.4.8.1. Italy: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.8.2. Italy: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.8.3. Italy: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.8.4. Italy: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.9. Ovarian Cancer Market - Spain
    • 9.4.9.1. Spain: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.9.2. Spain: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.9.3. Spain: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.9.4. Spain: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.10. Ovarian Cancer Market - Netherlands
    • 9.4.10.1. Netherlands: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.10.2. Netherlands: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.10.3. Netherlands: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.10.4. Netherlands: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.4.11. Ovarian Cancer Market - Russia
    • 9.4.11.1. Russia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.4.11.2. Russia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.4.11.3. Russia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.4.11.4. Russia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
• 9.5. Ovarian Cancer Market - Asia Pacific
  • 9.5.1. Asia Pacific: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 9.5.2. Asia Pacific: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 9.5.3. Asia Pacific: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 9.5.4. Asia Pacific: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.5. Ovarian Cancer Market - China
    • 9.5.5.1. China: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.5.2. China.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.5.3. China: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.5.4. China: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.6. Ovarian Cancer Market - India
    • 9.5.6.1. India: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.6.2. India.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.6.3. India: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.6.4. India: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.7. Ovarian Cancer Market - Japan
    • 9.5.7.1. Japan: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.7.2. Japan.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.7.3. Japan: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.7.4. Japan: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.8. Ovarian Cancer Market - Malaysia
    • 9.5.8.1. Malaysia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.8.2. Malaysia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.8.3. Malaysia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.8.4. Malaysia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.9. Ovarian Cancer Market - Indonesia
    • 9.5.9.1. Indonesia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.9.2. Indonesia.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.9.3. Indonesia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.9.4. Indonesia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.5.10. Ovarian Cancer Market - South Korea
    • 9.5.10.1. South Korea: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.5.10.2. South Korea.: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.5.10.3. South Korea: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.5.10.4. South Korea: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
• 9.6. Ovarian Cancer Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 9.6.2. Middle East & Africa: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 9.6.3. Middle East & Africa: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 9.6.4. Middle East & Africa: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.6.5. Ovarian Cancer Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.6.6. Ovarian Cancer Market - South Africa
    • 9.6.6.1. South Africa: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.6.6.2. South Africa: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.6.6.3. South Africa: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.6.6.4. South Africa: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.6.7. Ovarian Cancer Market - Israel
    • 9.6.7.1. Israel: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.6.7.2. Israel: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.6.7.3. Israel: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.6.7.4. Israel: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.6.8. Ovarian Cancer Market - UAE
    • 9.6.8.1. UAE: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.6.8.2. UAE: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.6.8.3. UAE: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.6.8.4. UAE: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
• 9.7. Ovarian Cancer Market - Latin America
  • 9.7.1. Latin America: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
  • 9.7.2. Latin America: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
  • 9.7.3. Latin America: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
  • 9.7.4. Latin America: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.7.5. Ovarian Cancer Market - Mexico
    • 9.7.5.1. Mexico: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.7.5.2. Mexico: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.7.5.3. Mexico: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.7.5.4. Mexico: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.7.6. Ovarian Cancer Market - Brazil
    • 9.7.6.1. Brazil: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.7.6.2. Brazil: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.7.6.3. Brazil: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.7.6.4. Brazil: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 9.7.7. Ovarian Cancer Market - Argentina
    • 9.7.7.1. Argentina: Ovarian Cancer Market, by Diagnosis, 2018 - 2030 (USD Billion)
    • 9.7.7.2. Argentina: Ovarian Cancer Market, by End-User, 2018 - 2030 (USD Billion)
    • 9.7.7.3. Argentina: Ovarian Cancer Market, by Therapeutic Treatment, 2018 - 2030 (USD Billion)
    • 9.7.7.4. Argentina: Ovarian Cancer Market, by Type, 2018 - 2030 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. AstraZeneca Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Aetera Zenteris Inc
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Bristol-Myers Squibb Corp
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Boehringer Ingelheim GmbH
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Eli Lilly and Company
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. GlaxoSmithKline plc
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Genentech Inc
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Johnson & Johnson Corp
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Janssen Pharmaceuticals, Inc.
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Novogen, Inc
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Oasmia Pharmaceutical Inc
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Pfizer Inc
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development
• 11.13. Roche Ltd.
  • 11.13.1. Company Overview
  • 11.13.2. Financial Performance
  • 11.13.3. Product Benchmarking
  • 11.13.4. Recent Development
• 11.14. Tesaro Inc.
  • 11.14.1. Company Overview
  • 11.14.2. Financial Performance
  • 11.14.3. Product Benchmarking
  • 11.14.4. Recent Development